A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Immunopharmacology and immunotoxicology
- Publicado em
- 18 ago 2022
- Citações
- 17
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Tong Liu, Shuai Jiang, Xue Teng, Lu Zhong, Mengmeng Liu, Yao Jin, Mei Dong
Descritores MeSH
- Colonic Neoplasms
- Paronychia
- Rectal Neoplasms
- Colorectal Neoplasms
- Exanthema
- Cetuximab
- Proto-Oncogene Proteins p21(ras)
- Panitumumab
- Antibodies, Monoclonal
- Antineoplastic Combined Chemotherapy Protocols
Veja também
Estudos relacionados
- Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes
- Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database
- Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis
- The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review